Pharmacological management of mild or moderate persistent asthma (Q36578777)

15 August 2017

1 reference

title

Pharmacological management of mild or moderate persistent asthma (English)

1 reference

15 August 2017

0 references

Paul M O'Byrne

1

0 references

author name string

Krishnan Parameswaran

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

368

1 reference

15 August 2017

issue

9537

1 reference

15 August 2017

page(s)

794-803

1 reference

Adult Asthma Consensus Guidelines update 2003.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Asthma control versus asthma severity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Control of asthma in Canada: failure to achieve guideline targets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

High or standard initial dose of budesonide to control mild-to-moderate asthma?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Daily versus as-needed corticosteroids for mild persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Regular versus symptomatic aerosol bronchodilator treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Regular inhaled beta-agonist treatment in bronchial asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Efficacy and safety of inhaled corticosteroids. New developments

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Long-term effects of budesonide or nedocromil in children with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Long-term inhaled corticosteroids in preschool children at high risk for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Intermittent Inhaled Corticosteroids in Infants with Episodic Wheezing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

A comparison of the efficacy and safety of inhaled corticosteroids in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Effect of long-term treatment with inhaled budesonide on adult height in children with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Long-term effect of budesonide on hypothalamic-pituitary-adrenal axis function in children with mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Treatment of asthma with drugs modifying the leukotriene pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

The effect of pranlukast on allergen-induced bone marrow eosinophilopoiesis in subjects with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Effect of long‐acting β2 agonists on exacerbation rates of asthma in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Cost-effectiveness of asthma control: an economic appraisal of the GOAL study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Standardised methodology of sputum induction and processing

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Induced sputum cell counts in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Inflammatory subtypes in asthma: assessment and identification using induced sputum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Changes in sputum eosinophils predict loss of asthma control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Predictors of loss of asthma control induced by corticosteroid withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

The predictive value of exhaled nitric oxide measurements in assessing changes in asthma control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Use of exhaled nitric oxide measurements to guide treatment in chronic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Anti-IgE for chronic asthma in adults and children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

A 15-Year Follow-up Study of Ventilatory Function in Adults with Asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Role for cysteinyl leukotrienes in allergen-induced change in circulating dendritic cell number in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

Effects of montelukast and budesonide on airway responses and airway inflammation in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969289-1

7 January 2021

10.1016/S0140-6736(06)69289-1

Identifiers

DOI

1 reference

15 August 2017

1 reference